The implementation of the Generating
Antibiotic Incentives Now Act and other recent efforts to speed antibiotic
development will only be successful if they encourage new chemical approaches
that address the dearth of new chemical classes in the antibiotics pipeline.
Antibiotic developers contacted by SciBX said solving bacteria-specific
challenges including rapidly emerging resistance and highly active drug export
will be addressed only by investing in new structure-guided synthesis and
Companies leading the charge to develop new classes of
antibiotics told SciBX that reliance on past approaches is not enough to
fill the pipeline. Instead, recent structural and chemical advances must guide
the discovery of the next generation of antibiotics.
The need for new chemical matter is particularly urgent for
Gram-negative bacterial infections, which present unique challenges to the
development of new drug classes.
The development of rapid diagnostic
tests to guide the clinical use of antibiotics also is a key next step to
encourage antibiotic development. Identifying the causative agent of an
infection is still a slow process relative to the lifetime of the infection;
thus, antibiotic efficacy and approval rates would benefit from such improved
Cain, C. SciBX 5(46); doi:10.1038/scibx.2012.1198
Published online Nov. 29, 2012
1. Spellberg, B. et al.
Clin. Infect. Dis. 46, 155-164 (2008)
2. Usdin, S. BioCentury
20(47), A1-A7; Nov. 19, 2012
3. Cain, C. BioCentury
20(23), A1-A4; June 4, 2012
4. Lou, K.-J. SciBX
AND INSTITUTIONS MENTIONED
Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif.
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Atlas Venture, Cambridge, Mass.
Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland
Biomedical Advanced Research and Development Authority, Washington, D.C.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Cempra Inc. (NASDAQ:CEMP), Chapel Hill, N.C.
Cubist Pharmaceuticals Inc., (NASDAQ:CBST), Lexington, Mass.
Curetis AG, Holzgerlingen, Germany
Food and Drug Administration, Silver Spring, Md.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Innovative Medicines Initiative, Brussels, Belgium
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Rib-X Pharmaceuticals Inc., New Haven, Conn.
(Euronext:SAN; NYSE:SNY), Paris, France
Tetraphase Pharmaceuticals Inc., Watertown, Mass.
Trius Therapeutics Inc. (NASDAQ:TSRX), San Diego, Calif.